Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Healthcare Antitrust Year-In-Review Webinar
Webinar
Antitrust
Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2026
Axinn Viewpoints
Antitrust
Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards
Awards & Recognitions
Antitrust
SABA North America Corporate Counsel Retreat 2026
Speaking Engagement
Antitrust
Axinn Promotes Lindsey Strang Aberg, Rebecca L. Clegg, Allison Vissichelli, and Eva Yung to Partner; Ricardo Camposanto, Danielle D. Irvine, and Josh Jowdy to Counsel
News
Antitrust